Plant-based meal delivery for multiple myeloma patients undergoing transplant
Implementing a Plant-Based Whole-Foods Meal Delivery Service for Patients Undergoing Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: A Pilot Study
This study is testing if a plant-based meal delivery service can improve gut health for people with multiple myeloma who are getting a stem cell transplant.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fred Hutchinson Cancer Center Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT06559709 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effects of a plant-based whole-foods meal delivery service on the gut microbiome of patients with multiple myeloma who are undergoing autologous hematopoietic cell transplantation. Participants will receive three meals and snacks delivered twice weekly, along with weekly meetings with a dietitian, during the peri-transplant period. The study aims to assess the feasibility of this dietary intervention and its potential to enhance microbial health, which is crucial for improving patient outcomes during treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are scheduled for their first autologous stem cell transplant for multiple myeloma and can follow the dietary intervention.
Not a fit: Patients with major psychiatric diagnoses that impair cognitive functioning or those who require inpatient transplantation may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the gut microbiome and overall health outcomes for patients undergoing stem cell transplantation.
How similar studies have performed: While the specific approach of a plant-based meal delivery service is novel, there is growing interest in dietary interventions for improving outcomes in transplant patients, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able to provide written informed consent prior to initiation of any study procedures * Planned first autologous stem cell transplantation for multiple myeloma * Planned outpatient treatment for the duration of transplantation (if admitted, the investigators will request that caregivers bring the meals/snacks to the hospital as they might with other food prepared at home) * Access to a refrigerator * Ability to reheat foods * Able to consume an oral diet at enrollment * Able to communicate clearly regarding aspects of the study: e.g. Give feedback on logistics and meals, in order to maximize the operational data the investigators can gather in this pilot study * At least 18 years of age Exclusion Criteria: * Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach, as judged by the patient's medical team * Planned inpatient transplantation
Where this trial is running
Seattle, Washington
- Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Kate Markey — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Kate Markey
- Email: kmarkey@fredhutch.org
- Phone: 206-667-7195
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.